Table 1.
Patient characteristics
| RA | AS | Total | |
|---|---|---|---|
| n | 24 | 16 | 40 |
| female:male | 21:3 | 3:13 | 24:16 |
| age (mean±SD)(range), years | 53.2±7.4 (35-77) | 42.1±10.9 (24-72) | 51.5±13.6 (24-77) |
| age at diagnosis (mean±SD)(range), years | 43.5±11.6 (29-58) | 29.2±8.9 (17-44) | 42.1±13.5 (17-58) |
| disease duration (mean±SD) (range), years | 8.7±8.5 (1-44) | 7.0±6.7 (1-26) | 8.3±7.8 (1-44) |
| RF positivity, n (%) | 17 (71) | - | - |
| ACPA positivity, n (%) | 14 (58) | - | - |
| DAS28 (baseline) (mean±SD) | 4.92±1.12 | - | - |
| BASDAI (baseline) (mean±SD) | - | 5.66±1.33 | - |
| Treatment (ETN, CZP) | 14 ETN, 10 CZP | 16 ETN | 30 ETN, 10 CZP |
| Low-dose corticosteroids (< 6 mg/day methylprednisone) | 8 | 1 | 9 |
| DXA L2-L4 osteoporosis (T-score <-2.5) | 2 | 1 | 3 |
| DXA L2-L4 osteopenia (T-score<-1) | 12 | 2 | 14 |
| DXA femoral neck osteoporosis (T-score<-2.5) | 1 | 1 | 2 |
| DXA femoral neck osteopenia (T-score<-1) | 11 | 5 | 16 |
| fragility fracture history | 7 | 6 | 13 |
Abbreviations: ACPA anti-citrullinated protein antibody, AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Acivity Index, CZP certolizumab pegol, DAS28 28-joint disease activity score, DXA dual-energy X-ray absorptiometry, ETN etanercept, RA rheumatoid arthritis, RF rheumatoid factor, SEM standard error of mean